Development and novel therapeutics in hepatocellular carcinoma: a review.
Development and novel therapeutics in hepatocellular carcinoma: a review.
复制标题
肝细胞癌的发展和新型治疗方法：评论。
DOI：
10.2147/tcrm.s92377
复制
发表时间：
2016
影响因子：
2.8
通讯作者：
Wong AS
中科院分区：
文献类型：
--
作者：
Ingle PV;Samsudin SZ;Chan PQ;Ng MK;Heng LX;Yap SC;Chai AS;Wong AS
本文综述了肝细胞癌的流行趋势、危险因素、预防策略(如疫苗接种、分期)、目前的新疗法，包括正在进行临床试验的药物，以及未来的治疗趋势。由于肝细胞癌是全世界与癌症相关的死亡的第三大常见原因，其总体发病率在发展中国家仍然高得惊人，而且在大多数发达国家和发展中国家都在稳步上升。在过去的15年里，肝癌的发病率增加了一倍多，并且随着年龄的增长而增加。慢性乙肝病毒感染是肝细胞癌的主要原因，其次是丙型肝炎病毒感染。其他导致肝细胞癌发生的因素包括酗酒、吸烟和代谢综合征(包括肥胖、糖尿病和脂肪肝)。在过去的几年里，治疗方案有所改善，特别是随着几种分子靶向疗法的批准。研究人员正在积极寻找治疗肝癌的新靶点和预测性生物标记物。在了解肝细胞癌的潜在机制方面取得了进展，这反过来可能导致新的治疗方法。尽管如此，仍有许多新兴药物仍在临床试验中，尚未显示出有希望的结果。因此，未来的治疗选择可能包括新的治疗干预措施的不同组合。
This review summarizes the epidemiological trend, risk factors, prevention strategies such as vaccination, staging, current novel therapeutics, including the drugs under clinical trials, and future therapeutic trends for hepatocellular carcinoma (HCC). As HCC is the third most common cause of cancer-related death worldwide, its overall incidence remains alarmingly high in the developing world and is steadily rising across most of the developed and developing world. Over the past 15 years, the incidence of HCC has more than doubled and it increases with advancing age. Chronic infection with hepatitis B virus is the leading cause of HCC, closely followed by infection with hepatitis C virus. Other factors contributing to the development of HCC include alcohol abuse, tobacco smoking, and metabolic syndrome (including obesity, diabetes, and fatty liver disease). Treatment options have improved in the past few years, particularly with the approval of several molecular-targeted therapies. The researchers are actively pursuing novel therapeutic targets as well as predictive biomarker for treatment of HCC. Advances are being made in understanding the mechanisms underlying HCC, which in turn could lead to novel therapeutics. Nevertheless, there are many emerging agents still under clinical trials and yet to show promising results. Hence, future therapeutic options may include different combination of novel therapeutic interventions.